Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 208 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Papillomavirus (HPV) Infection Clear all
Completed No phase listed Observational

Human Papillomavirus (HPV) Vaccination Among Survivors of Childhood Cancer

NCT01117389
View directory record Official record
Conditions
Human Papillomavirus
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
9 Years to 26 Years · Female only
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2015 · Synced Oct 9, 2026, 4:12 AM EDT
Completed Phase 1 Interventional

An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101

NCT02065973
View directory record Official record
Conditions
High-risk HPV Infection and Biopsy-proven CIN1
Interventions
R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7
Biological
Lead sponsor
PDS Biotechnology Corp.
Industry
Eligibility
21 Years to 65 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Port Jefferson, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 9, 2026, 4:12 AM EDT
Completed Phase 2 Interventional Results available

Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer

NCT01693783
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Human Papillomavirus Infection, Recurrent Cervical Carcinoma, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVB Cervical Cancer AJCC v6 and v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
5
States / cities
Duarte, California • Sacramento, California • South Pasadena, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 9, 2026, 4:12 AM EDT
Completed Phase 2 Interventional

Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer

NCT02048020
View directory record Official record
Conditions
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Larynx
Interventions
paclitaxel, carboplatin, intensity-modulated radiation therapy, quality-of-life assessment
Drug · Radiation · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 9, 2026, 4:12 AM EDT
Terminated Not applicable Interventional

Monitoring of Oral Human Papillomavirus Infection (HPV) in HPV-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)

NCT02045186
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions
Assessment of Oral HPV Infection
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 9, 2026, 4:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

NCT00423046
View directory record Official record
Conditions
Infections, Papillomavirus, Papillomavirus Vaccines
Interventions
GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM), Gardasil ® (Merck & Co. Inc), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
40
States / cities
Chandler, Arizona • San Diego, California • San Francisco, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 9, 2026, 4:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Culturally Tailored HPV Psychoeducational Multimedia Intervention

NCT06098690
View directory record Official record
Conditions
Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases, Intention, Adherence, Patient
Interventions
Culturally Tailored Multimedia Psychoeducational HPV Intervention, General HPV Multimedia Psychoeducational Control Group
Behavioral
Lead sponsor
University of Texas, El Paso
Other
Eligibility
18 Years to 45 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 9, 2026, 4:12 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)

NCT06611540
View directory record Official record
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
25 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
11
States / cities
Atlanta, Georgia • Louisville, Kentucky • Ann Arbor, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 9, 2026, 4:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Multilevel HPV Self-Testing Intervention for the Increase of Cervical Cancer Screening Among Women in Appalachia

NCT04411849
View directory record Official record
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
Best Practice, HPV Self-Collection, Informational Intervention, Patient Navigation Program
Other · Procedure · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
30 Years to 64 Years · Female only
Enrollment
802 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Lexington, Kentucky • Columbus, Ohio • Charlottesville, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 9, 2026, 4:12 AM EDT
Terminated Phase 1 Interventional

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

NCT02890368
View directory record Official record
Conditions
Solid Tumors, Mycosis Fungoides, Melanoma, Merkel-cell Carcinoma, Squamous Cell Carcinoma, Breast Carcinoma, Human Papillomavirus-Related Malignant Neoplasm, Soft Tissue Sarcoma
Interventions
TTI-621 Monotherapy, TTI-621 + PD-1/PD-L1 Inhibitor, TTI-621 + pegylated interferon-α2a, TTI-621 + T-Vec, TTI-621 + radiation
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Duarte, California • New York, New York • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 9, 2026, 4:12 AM EDT
Terminated Phase 1 Interventional Results available

Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers

NCT03912831
View directory record Official record
Conditions
Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer
Interventions
KITE-439, Cyclophosphamide, Fludarabine, Interleukin-2
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 9, 2026, 4:12 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Promoting HPV Vaccination Among Young Adults in Texas

NCT05057312
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Enhancing Accessibility to Health Care, Informational Intervention, Interview, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 26 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 9, 2026, 4:12 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Oral Warts in HIV+ Patients

NCT00454181
View directory record Official record
Conditions
Papillomatosis, HIV Infections
Interventions
Interferon-alpha, placebo
Drug · Other
Lead sponsor
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
San Francisco, California • Fort Lauderdale, Florida • Augusta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Oct 9, 2026, 4:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 9, 2026, 4:12 AM EDT
Completed No phase listed Observational

Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV

NCT01492842
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 24 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Aurora, Colorado • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 9, 2026, 4:12 AM EDT
Completed Phase 1 Interventional

Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.

NCT00000764
View directory record Official record
Conditions
HIV Infections, Anus Neoplasms
Interventions
Isotretinoin, Interferon alfa-2a
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 9, 2026, 4:12 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

NCT05266898
View directory record Official record
Conditions
Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection, Serology, Cervical Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Oral Cavity Infection
Interventions
Human papillomavirus 9-valent vaccine, recombinant, human papillomavirus vaccine, recombinant
Biological
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 9, 2026, 4:12 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study

NCT01133509
View directory record Official record
Conditions
Genital Human Papilloma Virus Infection
Interventions
Gardasil
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 9, 2026, 4:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Video-Assisted Counseling for HPV Vaccination

NCT03510091
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Counseling
Behavioral
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
9 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 9, 2026, 4:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination

NCT01153906
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Data collection
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Years to 25 Years · Female only
Enrollment
1,516 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 9, 2026, 4:12 AM EDT
Terminated Phase 2 Interventional Results available

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

NCT02706691
View directory record Official record
Conditions
FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Mutation, Head and Neck Squamous Cell Carcinoma, Human Papillomavirus Infection, Recurrent Head and Neck Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
Interventions
BGJ398
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 9, 2026, 4:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System

NCT01694875
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
APTIMA HPV Assay
Device
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
21 Years and older · Female only
Enrollment
2,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Minneapolis, Minnesota • Burlington, North Carolina • Maryville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Oct 9, 2026, 4:12 AM EDT
Active, not recruiting Phase 2 Interventional

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

NCT03074513
View directory record Official record
Conditions
Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis, Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma, Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Merkel Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Stage III Merkel Cell Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage III Pleural Malignant Mesothelioma AJCC v7, Stage IV Merkel Cell Carcinoma AJCC v7, Stage IV Nasopharyngeal Carcinoma AJCC v7, Stage IV Pleural Malignant Mesothelioma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7, Stage IVC Nasopharyngeal Carcinoma AJCC v7, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions
Atezolizumab, Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 9, 2026, 4:12 AM EDT
Active, not recruiting No phase listed Observational

Anal High-risk HPV, HSIL, and Microbiome Among Hispanic Peoples Living With HIV (PLWH)

NCT06651957
View directory record Official record
Conditions
Human Immunodeficiency Virus, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, High-Grade Squamous Intraepithelial Lesions
Interventions
Biospecimen Collection, Questionnaires
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 9, 2026, 4:12 AM EDT